Doctored Truths urges pharma to lead the fight against health misinformation
October 28, 2025 | Doctored Truths, Havas Lynx, Havas Village Manchester, Health Misinformation
“Doctored Truths” exposes the escalating crisis of health misinformation and disinformation, which has been ranked the world’s top short-term risk to the world, for the second year in a row. Havas Lynx calls upon the pharmaceutical industry to leverage its unique position and vast clinical data to combat this growing threat to patient health and public trust.
The Doctored Truths white paper highlights a critical erosion of trust in medical expertise, with proprietary Point.1 data revealing declining confidence in healthcare professionals (HCPs) across generations and only half of patients trusting non-government organisations like the World Health Organisation. As patients increasingly turn to digital platforms for health guidance, nearly one-third of social media health content now contains misinformation, leaving individuals vulnerable to conspiracy theories, viral fads, and unqualified advice.
The tangible impact of this misinformation overload is stark:
- Four out of five HCPs believe their patients have experienced physical or mental harm due to misinformation
- A third of patients regret a health decision made based on misinformation because they acted on misinformation
- 61% of HCPs report that misinformation has caused a loss of trust between them and their patients
This crisis is affecting every therapy area, undermining public health, social cohesion, and even economic stability, particularly impacting vulnerable groups where scientific understanding is limited or access to care is constrained.
“The spread of health misinformation isn’t just a concern; it’s a profound threat to patient well-being and the very foundation of evidence-based medicine,” says Claire Knapp, Chief Executive Officer at Havas Lynx. “Our ‘Doctored Truths’ white paper not only illuminates the scale of this problem but also underscores the immense responsibility and opportunity for the pharmaceutical industry. Pharma could hold the antidote – with its deep scientific expertise and extensive reach, it is uniquely positioned to reclaim trust and safeguard health outcomes. It’s not just an ethical imperative, but a strategic necessity for the industry’s future.”
The expectations for the pharmaceutical sector to act are clear. Point.1 data shows that 71% of HCPs believe pharma has a responsibility to tackle misinformation, yet only 41% feel enough is currently being done. Havas Lynx asserts that by stepping up to this challenge, pharma can not only shape its future reputation but also reinforce the very foundations of evidence-based healthcare.
Read the full “Doctored Truths” report and learn how your organisation can contribute to this vital initiative here.
This content was provided by Havas Lynx
Company Details
Latest Content from Havas Lynx
THE HIDDEN LIFESAVERS: overdose prevention campaign launches nationwide
The campaign encourages people who use drugs to do something remarkable – save a life
Andi Goes – the children’s book that helps detect early signs of dyslexia
Havas Lynx Group have launched a children’s book aimed at raising awareness and detecting early signs of dyslexia. Helping to make sure that parents have the support they need whilst…
Neurofibromatosis: a condition that’s hard to say, but even harder to live with
The Childhood Tumour Trust and Havas Lynx Group have launched a campaign to raise awareness and funds for people living with a rare genetic condition, neurofibromatosis 1 (NF1).
Havas Health & You Launches Behind the Mask, a Global Research Initiative to Document Health Experiences During the COVID-19 Pandemic and Beyond
Havas Health & You (HH&Y) have launched the details of a long-term global research project, Behind the Mask, a longitudinal, multi-armed study which focuses on documenting the ongoing evolution of…
Media Means Business
Creating meaningful media experiences in pharma
Havas Lynx Group elevates Jon Chapman and Paul Kinsella to CCOs
Havas Lynx Group announces the promotion of Jon Chapman and Paul Kinsella from Executive Creative Directors (ECD) to Chief Creative Officers (CCO) for Havas Lynx Group.
Elizabeth Egan appointed President of Havas Lynx Group
Europe’s largest healthcare communications agency has appointed a new President to help it build on a record year.